The National Advisory Committee on Immunization (NACI) recommends pneumococcal vaccination for prevention of invasive pneumococcal disease (IPD) and community-acquired pneumonia (CAP) in the following people:

1. All adults 65 years of age and older

2. Adults with non-immunocompromising conditions, such as:
   - chronic cerebrospinal fluid (CSF) leak
   - chronic neurologic conditions that may impair clearance of oral secretions
   - cochlear implants (including adults who are to receive implants)
   - chronic cardiac or pulmonary disease
   - diabetes mellitus
   - chronic kidney disease
   - chronic liver disease (including hepatic cirrhosis due to any cause)
   - asthma that required medical care in the preceding 12 months

3. Adults with immunocompromising conditions, such as:
   - sickle cell disease or other hemoglobinopathies
   - congenital immunodeficiencies involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin or factor D deficiencies), or phagocytic functions
   - asplenia (functional or anatomic)
   - immunocompromising therapy including use of long-term corticosteroids, chemotherapy, radiation therapy, post-organ transplant therapy, and biologic agents used for treatment of inflammatory conditions (e.g. such as inflammatory bowel disease or types of arthritis).
   - HIV infection
   - hematopoietic stem cell transplant (HSCT) (recipient)
   - malignant neoplasms including leukemia and lymphoma
   - nephrotic syndrome
   - solid organ or islet transplant (candidate or recipient)

4. Adults who are less than 65 years of age in long-term care facilities

5. Immunocompetent adults who have conditions or situations putting them at increased risk of pneumococcal disease, including:
   - alcoholism
   - smoking
   - homelessness
   - illicit drug use

**PNEUMOCOCCAL VACCINES**

1. Conjugate pneumococcal vaccine
   - Prevnar®13 (PNEU-C-13)

2. Polysaccharide pneumococcal vaccine
   - Pneumovax®23 (PNEU-P-23)

For more information, visit the National Advisory Committee on Immunization (NACI) website at [https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci.html](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci.html)
DOSAGE AND SCHEDULE

The dose of the pneumococcal vaccine for all age groups is 0.5 mL.

1. Immunocompetent adults 65 years of age and older with no risk factors
   - NACI recommends the administration of one dose of PNEU-P-23.*
   - For additional protection against CAP and IPD, NACI recommends the administration of PNEU-C-13 can be considered for:
     - Adults not previously immunized against pneumococcal disease: PNEU-C-13 should be provided first, followed by PNEU-P-23 at least 8 weeks later.
     - Adults previously immunized against pneumococcal disease: PNEU-C-13 should be administered at least one year after any previous dose of PNEU-P-23.*
   *PNEU-P-23 should be administered at least 5 years after any previous PNEU-P-23 dose.

2. Immunocompetent adults less than 65 years of age in long-term care facilities
   - Administer one dose of PNEU-P-23.

3. Adults with an immunocompromising condition (except HSCT)
   - Administer one dose of PNEU-C-13 followed 8 weeks later by one dose of PNEU-P-23 (if not previously immunized with PNEU-P-23). The PNEU-C-13 dose should be administered at least one year after any previous dose of PNEU-P-23.

4. Adult HSCT recipients
   - Administer three doses of PNEU-C-13 starting 3-9 months after transplant. These doses should be administered at least 4 weeks apart, followed by a dose of PNEU-P-23 12 to 18 months post-transplant (i.e. 6 to 12 months after the last dose of PNEU-C-13).

RE-IMMUNIZATION

- A second dose of PNEU-P-23 is recommended for adults of any age with an immunocompromising condition (except HSCT) that places them at highest risk of IPD. If a booster dose of PNEU-P-23 is recommended, it should be administered at least 5 years after the previous dose of PNEU-P-23 vaccine. For adult HSCT recipients, one booster dose with PNEU-P-23, is recommended as early as 1 year.

CONTRAINDICATIONS AND PRECAUTIONS

Pneumococcal vaccines are contraindicated in any individual with a history of anaphylaxis to any component of the vaccines, including diphtheria toxoid.

ADVERSE REACTIONS

- Soreness or redness at the injection site.
- Occasional slight fever may occur.
- Very rarely, moderate to severe reactions may occur.

OTHER CONSIDERATIONS AND COUNSELING POINTS

- PNEU-C-13 can be co-administered with other vaccines, but not with PNEU-P-23.
- PNEU-P-23 vaccine and HZ vaccine may be administered together.
- Pneumococcal vaccine may be given year-round.
- Pregnant women can be vaccinated with PNEU-P-23 or PNEU-C-13 vaccine, if indicated.